PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 39/12, A61P 31/20 — A1

(11) International Publication Number: WO 00/35478

(43) International Publication Date: 22 June 2000 (22.06.00)

(21) International Application Number: PCT/AU99/01108

(22) International Filing Date: 13 December 1999 (13.12.99)

(30) Priority Data:
PP 7653 11 December 1998 (11.12.98) AU

(71) Applicant *(for all designated States except US)*: THE UNIVERSITY OF QUEENSLAND [AU/AU]; St Lucia, Brisbane, QLD 4072 (AU).

(71) Applicant *(for US only)*: SUN, Xiao, Yi (legal representative of the deceased inventor) [AU/AU]; 21 Cooranga Street, Jindalee, QLD 4074 (AU).

(72) Inventor: ZHOU, Jian (deceased).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: FRAZER, Ian [AU/AU]; Centre For Immunology & Cancer Research, University Of Queensland, Department Of Medicine, Princess Alexandra Hospital, Buranda, QLD 4102 (AU).

(74) Agent: FISHER ADAMS KELLY; Level 13, Amp Place, 10 Eagle Street, Brisbane, QLD 4000 (AU).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: TREATMENT OF PAPILLOMAVIRUS INFECTIONS

(57) Abstract

This invention relates to treatment of papillomavirus infections. Primarily there is provided a method of treatment of an existing papillomavirus (PV) infection which includes the step of administration of PV VLPs selected from the group consisting of PV L1 VLPs and PV L1/L2 VLPs to a patient suffering from the PV infection. Suitably the PV infection is characterised by the presence of epithelial lesions. The major infection which is treated are genital warts caused by HPV 6 and HPV 11.